Phase I PIANO trial-PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes.
R SundarD K A ChiaJ J ZhaoA R Y B LeeG KimH L TanA PangA ShabbirW WillaertH MaK K HuangT HagiharaA L K TanC-A J OngJ S M WongC J SeoR WalshG ChanS W CheoC C C SohE CalleboutK GeboesM C H NgJ H Y LumW Q LeowS SelvarajanA HoorensW H AngH PangP TanW P YongC S L ChiaW CeelenJ B Y SoPublished in: ESMO open (2024)
The first-in-human trial combining PIPAC-OX and nivolumab demonstrated safety and tolerability, coupled with enhanced T-cell infiltration within peritoneal tumors. This trial sets the stage for future combinations of systemic immunotherapy with locoregional intraperitoneal treatments.